Natalie S. Callander, MD, University of Washington Carbone Cancer Center

Multiple Myeloma: Unmet Needs and Future Directions in Care

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

August 8th 2023

After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

August 8th 2023

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

Combination Strategies With Bispecifics in Multiple Myeloma

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

August 1st 2023

Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.

Bispecifics in Multiple Myeloma: Adverse Event Management

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

August 1st 2023

Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.

Bispecifics in Multiple Myeloma: Dosing and Transition of Care

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

July 25th 2023

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

July 25th 2023

Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.

Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

July 18th 2023

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.

Factors in Selecting Therapy at First Relapse in Multiple Myeloma

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

July 18th 2023

Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.

Patient Scenario: Treatment Options in MM at First Relapse

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

July 11th 2023

Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.

Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

July 11th 2023

A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.

Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

July 4th 2023

Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.

Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

July 4th 2023

Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.

Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

June 27th 2023

Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.

Induction Therapy Regimens for Transplant-Eligible NDMM

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

June 27th 2023

Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.

NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

June 20th 2023

Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.

What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai;Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Alfred L. Garfall, MD, Abramson Cancer Center;Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

June 20th 2023

Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.